# Enrichment of mutated DNA enables ultra-sensitive ctDNA detection in NSCLC using shallow targeted sequencing

Source: https://onco.cc/key-papers/paper-labrousse-enspyre-sci-rep-2026/  
OnCo record `paper-labrousse-enspyre-sci-rep-2026` (Key paper). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A chemistry that enriches the tumour's mutated DNA before sequencing found lung cancer DNA at a few parts per million with far less sequencing than usual.

## Summary

Enspyre is a ctDNA enrichment method. Tumour and, where available, matched normal tissue from eight lung cancer patients were whole-genome sequenced; custom capture panels ran on 72 samples of patient plasma diluted into healthy donor plasma (nine per subject) and eight healthy donor controls. Enspyre reached 100 per cent (6 of 6) detection down to 10 parts per million and called residual disease as low as 5 parts per million with no false positives, at a median DNA input of 7.67 ng, without molecular barcodes, with a median of 9.6 million read pairs per sample. The authors note that larger studies are needed.

## Fields

- Kind: Key paper
- Last checked: 2026-11-04
- Journal: Scientific Reports
- Year: 2026
- DOI: 10.1038/s41598-026-57421-5
- Authors: Labrousse P, Russell H, Stetson D, et al.
- Findings: 6 of 6 detected at 10 ppm; calls down to 5 ppm; no false positives.; Median input 7.67 ng; median 9.6 million read pairs.
- What it means: Enrichment may make parts-per-million testing possible on small sequencers, though only eight patients were studied.
- Caveats: Eight patients, diluted plasma.

## Sources

- Labrousse et al., Sci Rep 2026: https://doi.org/10.1038/s41598-026-57421-5
- PubMed: https://pubmed.ncbi.nlm.nih.gov/42288656/

## Connected records

- cancers: [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/)
- fronts: [Diagnostics & Biomarkers](https://onco.cc/fronts/diagnostics/)
- technologies: [MRD / molecular residual disease testing](https://onco.cc/technologies/mrd-testing/)
- drugs: [Enspyre](https://onco.cc/drugs/enspyre-mrd/)
- companies: [Biofidelity](https://onco.cc/companies/biofidelity/)
- terms: [Circulating tumour DNA (ctDNA)](https://onco.cc/terms/ctdna/), [Minimal / molecular residual disease (MRD)](https://onco.cc/terms/mrd/), [Tumour-informed versus tumour-naive ctDNA assays](https://onco.cc/terms/tumour-informed-assay/)

---
JSON: https://onco.cc/api/v1/entities/paper-labrousse-enspyre-sci-rep-2026.json